Project Grant R01CA296000
Award Date 8/1/25
Completion Date 7/31/29
Dollars Obligated $2.6M
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Texas, USA
Similar Awards
- This federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $680,334 in funding to the Icahn School of Medicine at Mount Sinai to investigate the cellular and molecular mechanisms driving age-associated pro-tumoral myelopoiesis. The 5-year research project aims to elucidate how aging of the immune system, independent of stromal age, promotes inflammation and tumor progression. The researchers will conduct high-dimensional profiling of...
- This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $465,020 to the University of Maryland, Baltimore (UMB) to conduct research on the mechanisms by which chemotherapy can inadvertently promote metastasis in epithelial ovarian cancer. The research aims to determine how clinically approved chemotherapies activate tumor-associated membrane-anchored serine proteases (MASPs) in a way that potentiates tumor dissemination and metastatic...
- This Project Grant award of $576,723.00 was provided by the National Institute on Aging (NIA), a component of the U.S. Department of Health and Human Services, under the Aging Research federal grant program (CFDA 93.866). The award supports research to investigate the role of senescent cancer-associated fibroblasts (SenCAFs) in the progression of breast cancer, particularly in older individuals. Key objectives include determining the organ-specific effects of SenCAFs on metastatic breast...
- This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $564,695.00 in funding to The University of Texas M.D. Anderson Cancer Center to study a new driver and therapeutic vulnerability of bone metastasis. The research aims to explore the role of the protein Acyl-CoA Binding Protein (ACBP) in promoting bone metastasis through regulating lipid metabolism, fatty acid oxidation, and protection against lipid peroxidation and ferroptotic cell...
- The National Cancer Institute (CFDA 93.396 - Cancer Biology Research) awarded a $510,431 Project Grant to The Johns Hopkins University to conduct research on recurrence and resistance in the aging melanoma microenvironment. The research aims to uncover how the aging immune microenvironment influences tumor dormancy and therapeutic resistance in melanoma. Key focus areas include understanding the role of aged lung fibroblasts and their impact on melanoma cell dormancy and reactivation through Wnt...
- This $150,104 Project Grant award from the National Cancer Institute's Cancer Research Manpower program (CFDA 93.398) supports research to understand the evolutionary trajectories of complex genomic rearrangements in cancer. The project aims to develop novel computational approaches, "AGAVE" and "ROSE", to characterize the timing and dynamics of focal amplifications and structural variants during tumor evolution. The research will map these evolutionary patterns across...
- This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $388,750 to The Washington University to conduct research on the role of senescent cancer-associated fibroblasts (senCAFs) in breast cancer progression. The key objectives are to: 1) Determine the organ-specific effects of senCAFs on metastatic breast cancer progression; 2) Examine how senCAFs impact extracellular matrix dynamics and tumor cell migration; and 3) Assess the impact of senCAFs on...
- This $421,685 Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to the University of Texas MD Anderson Cancer Center supports research to investigate how the LIFR-LCN2 pathway in liver cancer restricts the cytotoxic function of CD8+ T cells, leading to immune evasion and resistance to immunotherapy. The central hypothesis is that loss of LIFR upregulates LCN2 in liver cancer, thereby suppressing the abundance and cytotoxic function of CD8+...
- This federal Project Grant award from the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program provides $754,766.00 to The University of Texas M.D. Anderson Cancer Center to investigate the role of microbiota and microbial extracellular vesicles in metastatic dormancy in melanoma. The award period runs from November 1, 2024 to October 31, 2027. The University of Texas M.D. Anderson Cancer Center is a prominent academic medical center with extensive...
- This federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $506,309 to study the regulation of ovarian cancer metastasis by microenvironment-induced chromatin accessibility and c-Jun activation. The key objectives are to determine the mechanism by which microenvironmental signals activate c-Jun in ovarian cancer cells, and how this leads to increased transcription of c-Jun target genes necessary for metastatic colonization. The project...